Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

NCT04596319 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis
Pseudomonas Aeruginosa
Pseudomonas
Lung Infection
Lung Infection Pseudomonal

Interventions

BIOLOGICAL: AP-PA02
OTHER: Placebo

Sponsor

Armata Pharmaceuticals, Inc.

Collaborators

[object Object]